Bayer, facing tens of thousands of lawsuits over weedkiller Roundup, has set its sights on the Supreme Court. Dale Mullen, partner and co-chair of the business and corporate law section at Whiteford, joins Bloomberg Intelligence litigation analyst Holly Froum on this episode of the Votes and Verdicts podcast to discuss Bayer Monsanto’s appeal to the US Supreme Court of a $1.25 million verdict holding it liable for failing to warn that Roundup causes cancer. They discuss Bayer’s arguments, the company’s chance of success on appeal, risks that remain even if it secures a Supreme Court victory and more.

See omnystudio.com/listener for privacy information.

What are the impacts of the Trump administration’s rescheduling of state-licensed medical cannabis to Schedule III from Schedule I? Could federal rescheduling extend to recreational marijuana later this year? If so, how should companies, firms and operators prepare for a world where significant tax relief and growth opportunities emerge? Would Congress face pressure to consider a federal tax on the budding sector if broader cannabis reform is in the cards? Foley Hoag Partner Jeffrey Schultz joins Bloomberg Intelligence’s Nathan Dean and Holly Froum on this episode of the Votes and Verdicts podcast to discuss these and other questions facing the industry.

See omnystudio.com/listener for privacy information.

UCLA Law Professor William Boyd joins Bloomberg Intelligence litigation analyst Holly Froum on this episode of the Votes and Verdicts podcast to discuss Bayer’s appeal to the US Supreme Court of a $1.25 million verdict holding it liable for failing to warn that weedkiller Roundup causes cancer. They discuss Bayer’s arguments, the arguments’ vulnerabilities and how the court is likely to rule. They also explore the potential immunity Bayer has from future product-liability lawsuits concerning glyphosate products pursuant to a February executive order.

See omnystudio.com/listener for privacy information.